Australian Scientists Find New Way to Fight Drug-Resistant TB

Scientists in Australia have unlocked a secret weapon against one of the world's deadliest diseases, offering fresh hope for millions battling drug-resistant tuberculosis.

A research team at the University of Melbourne, working with Australia's national science facilities, discovered how a critical enzyme in TB bacteria gets activated. Think of it like finding the light switch in a dark room: instead of fumbling for the bulb itself, they can now just flip the switch off.

The enzyme, called ICL2, acts like a survival tool for TB bacteria when they're under attack inside the human body. When the bacteria run low on sugar, they switch to living on fats, and ICL2 makes that possible.

Traditional TB drugs try to block the enzyme's active site directly, like trying to jam a lock. But this new discovery reveals an "allosteric mechanism," a hidden control point that turns the enzyme on and off. It's much easier to target and unique to TB bacteria, meaning treatments could be more effective with fewer side effects.

The team used three cutting-edge tools at the Australian Synchrotron and National Deuteration Facility to crack the code. High-powered X-rays revealed the enzyme's exact atomic structure when locked in place, while other techniques showed how it moves and changes shape in its natural, flowing state inside cells.

Dr. Ashish Sethi, who helped lead the research, explained that the enzyme is so flexible in its inactive state that it couldn't even be crystallized for study. That flexibility is exactly why it doesn't work well until its activator shows up.

Why This Inspires

This breakthrough matters beyond the laboratory walls. Tuberculosis still affects thousands of Australians each year, with rates four to five times higher among Aboriginal and Torres Strait Islander peoples compared to other Australian-born populations.

Drug-resistant TB has been growing worldwide, making treatment harder and more expensive. This discovery opens a completely new pathway for developing medications that work differently than anything currently available.

The research, published in Nature Communications Biology, represents years of collaboration between the University of Melbourne, the University of Auckland, and Monash University. It showcases how Australia's advanced scientific infrastructure can tackle global health challenges.

By targeting the enzyme's control switch rather than its active site, future drugs could be more precise and powerful against strains that have become resistant to standard treatments. The team's success in making the invisible visible through deuteration and advanced imaging proves that sometimes the most powerful solutions come from seeing things in a completely new light.